Erbitux adds 5 weeks to lung cancer survival
May 31st, 2008
 Lung cancer patients treated in a large clinical trial with ImClone Systems Inc’s Erbitux and chemotherapy lived about five weeks longer than patients treated with chemotherapy alone, according to study results released on Saturday.